Although early administration of TNF-α-blockers was shown to be beneficial in pediatric patients with IBD (18, 19), this practice does not appear to be very common yet, as only 11.4% of patients received a biological drug immediately after diagnosis. This evidence concerns the gene TNF and inflammatory bowel disease.